Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor.
Mammary tumours are oestrogen dependent in female Sprague-Dawley rats and in a significant proportion of women, so pharmacological treatment to inhibit oestrogen production is a valuable therapeutic measure to prevent or slow the progression of disease. Here we show that a non-steroidal aromatase inhibitor, which competitively inhibits the conversion of androstenedione to oestrone, prevents the development of both benign and malignant spontaneous mammary neoplasms in female Sprague-Dawley ats. It also slows the spontaneous development of pituitary pars distalis adenomas in female rats, and reduces the incidence of spontaneous hepatocellular tumours in male and female rats.
Gunson
D E
DE
Division of Preclinical Safety, Ciba-Geigy Corporation, Summit, New Jersey 07901, USA.
Steele
R E
RE
Chau
R Y
RY
D000818:Animals; D047072:Aromatase Inhibitors; D017316:Fadrozole / Q000627:therapeutic use*; D005260:Female; D008113:Liver Neoplasms / Q000517:prevention & control; D008297:Male; D015674:Mammary Neoplasms, Animal / Q000517:prevention & control*; D010911:Pituitary Neoplasms / Q000517:prevention & control; D051381:Rats; D017207:Rats, Sprague-Dawley
D047072:Aromatase Inhibitors; D017316:Fadrozole